Skip to main content
. 2023 Jun 28;51(14):7288–7313. doi: 10.1093/nar/gkad538

Figure 4.

Figure 4.

Effects of a CDK8/19-degrading PROTAC. (A) Chemical structure of the CDK8/19-degrading PROTAC SNX7886. (B) Immunoblotting analysis of CDK8, CDK19 and CCNC expression in 293 cells treated for 24 h with BI1347 or SNX7886 at the indicated concentrations. (C) Volcano plots of the effects of 72-hr treatment with 200 nM SNX7886 versus vehicle control (parental (WT) cells), 200 nM SNX7886 versus 200nM BI1347 (parental cells) and 200 nM SNX7886 versus vehicle control (dKO cells). (D) Overlap of DEGs affected by BI1347 or SNX7886 treatment. (E) Heatmap of 82 DEGs differentially affected by SNX7886 and BI1347 in WT cells under indicated conditions. (F) Heatmap of DEGs that are affected by Senexin B or CDK8/19 expression (see Supplementary Figure S4A) and regulated by SNX7886 under indicated conditions. (G) Overlap of DEGs affected by SNX7886 treatment or dKO. (H) Heatmap of the genes regulated by all CDK8/19 inhibitors or PROTAC but not by dKO under indicated conditions.